New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results